Efficacy of brodalumab in psoriasis patients with a body weight >100 kg: Real‐world evidence (RWE) from the LIBERO study
Abstract Background Patients with psoriasis often suffer from obesity. However, only limited data are available on the efficacy of brodalumab 210 mg, a fully human monoclonal immunoglobulin IgG2 antibody binding to the human interleukin 17 receptor subunit A, in obese patients in daily practice, to...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-03-01
|
| Series: | JEADV Clinical Practice |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/jvc2.556 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850099116889079808 |
|---|---|
| author | Ralph vonKiedrowski Khusru Asadullah Bernhard Korge Konstantina Tsarovina Matthias Augustin |
| author_facet | Ralph vonKiedrowski Khusru Asadullah Bernhard Korge Konstantina Tsarovina Matthias Augustin |
| author_sort | Ralph vonKiedrowski |
| collection | DOAJ |
| description | Abstract Background Patients with psoriasis often suffer from obesity. However, only limited data are available on the efficacy of brodalumab 210 mg, a fully human monoclonal immunoglobulin IgG2 antibody binding to the human interleukin 17 receptor subunit A, in obese patients in daily practice, to date. Objectives A subgroup analysis from the LIBERO study was conducted to compare the effectiveness of brodalumab in patients weighing ≤100 and >100 kg after ~12 weeks (W) and ~52 W. Methods LIBERO is a large prospective, multicenter, non‐interventional, real‐world‐evidence study including adult patients with plaque psoriasis treated with brodalumab 210 mg. Results Four hundred and sixty‐one patients with a body weight up to 100 kg (nonobese) and 161 patients with >100 kg body weight (obese) were included in this subgroup analysis. At baseline, the majority of patients in both groups had very severe (12.6%; 15.7%) or severe (49.4%; 55.0%) psoriasis, as assessed by Physician Global Assessment (PGA). As of W2, a significant reduction of the mean PASI could be achieved in both groups. In patients weighing ≤100 kg mean PASI decreased from 16.9 to 9.0 and further improved to 2.6 at ~W12 (p < 0.001). In the patient group >100 kg, the PASI decreased from 17.9 to 10.2 at ~W2 (p < 0.001) and improved further to 3.9 at ~W12 (p < 0.001). However, at ~W12 absolute PASI0‐3 rates were lower in patients >100 kg than in patients ≤100 kg (68.4% vs. 80.5%, p = 0.006); there was no statistically significant difference between the groups at ~W52/last visit any more in any of the effectiveness parameters with, for example, a PGA0/1 response of 82.3% versus 86.5% (p = 0.6089), respectively. Conclusions This subgroup analysis of LIBERO confirmed, that in daily practice brodalumab can be equally beneficial patients with >100 and ≤100 kg in the long‐term management of psoriasis. |
| format | Article |
| id | doaj-art-34993ea5039449548a5bf2f00aa564a4 |
| institution | DOAJ |
| issn | 2768-6566 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Wiley |
| record_format | Article |
| series | JEADV Clinical Practice |
| spelling | doaj-art-34993ea5039449548a5bf2f00aa564a42025-08-20T02:40:33ZengWileyJEADV Clinical Practice2768-65662025-03-014119520210.1002/jvc2.556Efficacy of brodalumab in psoriasis patients with a body weight >100 kg: Real‐world evidence (RWE) from the LIBERO studyRalph vonKiedrowski0Khusru Asadullah1Bernhard Korge2Konstantina Tsarovina3Matthias Augustin4Medical Study & Service Selters GmbH Selters/Ww GermanyDermatological Practice Potsdam Dermatology MVZ Potsdam GermanyDermatological Practice Düren GermanyLEO Pharma GmbH Neu‐Isenburg GermanyGerman Center for Health Services Research in Dermatology (CVderm), Institute for Health Services Research in Dermatology and Nursing (IVDP) University Medical Center Hamburg‐Eppendorf (UKE) Hamburg GermanyAbstract Background Patients with psoriasis often suffer from obesity. However, only limited data are available on the efficacy of brodalumab 210 mg, a fully human monoclonal immunoglobulin IgG2 antibody binding to the human interleukin 17 receptor subunit A, in obese patients in daily practice, to date. Objectives A subgroup analysis from the LIBERO study was conducted to compare the effectiveness of brodalumab in patients weighing ≤100 and >100 kg after ~12 weeks (W) and ~52 W. Methods LIBERO is a large prospective, multicenter, non‐interventional, real‐world‐evidence study including adult patients with plaque psoriasis treated with brodalumab 210 mg. Results Four hundred and sixty‐one patients with a body weight up to 100 kg (nonobese) and 161 patients with >100 kg body weight (obese) were included in this subgroup analysis. At baseline, the majority of patients in both groups had very severe (12.6%; 15.7%) or severe (49.4%; 55.0%) psoriasis, as assessed by Physician Global Assessment (PGA). As of W2, a significant reduction of the mean PASI could be achieved in both groups. In patients weighing ≤100 kg mean PASI decreased from 16.9 to 9.0 and further improved to 2.6 at ~W12 (p < 0.001). In the patient group >100 kg, the PASI decreased from 17.9 to 10.2 at ~W2 (p < 0.001) and improved further to 3.9 at ~W12 (p < 0.001). However, at ~W12 absolute PASI0‐3 rates were lower in patients >100 kg than in patients ≤100 kg (68.4% vs. 80.5%, p = 0.006); there was no statistically significant difference between the groups at ~W52/last visit any more in any of the effectiveness parameters with, for example, a PGA0/1 response of 82.3% versus 86.5% (p = 0.6089), respectively. Conclusions This subgroup analysis of LIBERO confirmed, that in daily practice brodalumab can be equally beneficial patients with >100 and ≤100 kg in the long‐term management of psoriasis.https://doi.org/10.1002/jvc2.556daily practiceIL‐17RA antagonistnon‐interventional studyobesity |
| spellingShingle | Ralph vonKiedrowski Khusru Asadullah Bernhard Korge Konstantina Tsarovina Matthias Augustin Efficacy of brodalumab in psoriasis patients with a body weight >100 kg: Real‐world evidence (RWE) from the LIBERO study JEADV Clinical Practice daily practice IL‐17RA antagonist non‐interventional study obesity |
| title | Efficacy of brodalumab in psoriasis patients with a body weight >100 kg: Real‐world evidence (RWE) from the LIBERO study |
| title_full | Efficacy of brodalumab in psoriasis patients with a body weight >100 kg: Real‐world evidence (RWE) from the LIBERO study |
| title_fullStr | Efficacy of brodalumab in psoriasis patients with a body weight >100 kg: Real‐world evidence (RWE) from the LIBERO study |
| title_full_unstemmed | Efficacy of brodalumab in psoriasis patients with a body weight >100 kg: Real‐world evidence (RWE) from the LIBERO study |
| title_short | Efficacy of brodalumab in psoriasis patients with a body weight >100 kg: Real‐world evidence (RWE) from the LIBERO study |
| title_sort | efficacy of brodalumab in psoriasis patients with a body weight 100 kg real world evidence rwe from the libero study |
| topic | daily practice IL‐17RA antagonist non‐interventional study obesity |
| url | https://doi.org/10.1002/jvc2.556 |
| work_keys_str_mv | AT ralphvonkiedrowski efficacyofbrodalumabinpsoriasispatientswithabodyweight100kgrealworldevidencerwefromtheliberostudy AT khusruasadullah efficacyofbrodalumabinpsoriasispatientswithabodyweight100kgrealworldevidencerwefromtheliberostudy AT bernhardkorge efficacyofbrodalumabinpsoriasispatientswithabodyweight100kgrealworldevidencerwefromtheliberostudy AT konstantinatsarovina efficacyofbrodalumabinpsoriasispatientswithabodyweight100kgrealworldevidencerwefromtheliberostudy AT matthiasaugustin efficacyofbrodalumabinpsoriasispatientswithabodyweight100kgrealworldevidencerwefromtheliberostudy |